---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-23-000068"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:01:37.913528+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q3 net sales down 7.1% YoY to $632.1M; lowers full-year 2023 outlook

## Summary
- Net sales $632.1M, down 7.1% YoY; currency-neutral decline 7.9%; COVID sales dropped to $0.3M from $17.2M.
- Life Science segment sales $263.5M, down 17.1% YoY (currency-neutral -17.8%); diagnostics segment up 1.7%.
- Net income $106.3M ($3.64 diluted EPS) vs net loss of $162.8M ($5.48 loss) in prior year, driven by Sartorius fair value changes.
- Operating income $90.9M vs $94.6M; gross margin 53.1% vs 54.7%.
- CEO cites further deterioration in biopharma/biotech spending and China challenges; full-year FY2023 outlook lowered.

## SEC filing metadata
- accession: 0000012208-23-000068
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/0000012208-23-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/bio-20231026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-23-000068
- JSON: https://secwatch.observer/filing/0000012208-23-000068.json
- Plain text: https://secwatch.observer/filing/0000012208-23-000068.txt

## Key facts
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported the third quarter ended September 30, 2023 results: revenue $632.1 million, net income $106.3 million, EPS $3.64 per share. Guidance lowered.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $632.1 million
  - Net income: $106.3 million
  - EPS: $3.64 per share
  - Guidance: lowered
  - Result: preliminary results
  source text: life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.9 percent compared to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/0000012208-23-000068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.